The Top Five Deals Of 2015 (And A Few That Fell Apart)
This article was originally published in Scrip
It's obvious which transaction (or pending transaction) is deal of the year for 2015 even without being told, right? Of course, it's the $160bn merger between Pfizer Inc. and Allergan PLC, not just because it will create the biggest pharma company and the biggest health care company in the world, but also because of the deals that had to occur for the merger to make sense and because of the deals that may follow on its heels in 2016.
You may also be interested in...
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.